What side effects are common with any peptide injection?
Reactions at the injection site are the most common side effect across peptides. Expect the occasional small red spot, itch, bruise or tender bump where the needle went in. MedlinePlus notes that some soreness is to be expected with injections under the skin, and recommends changing sites each time.
Tesamorelin, the peptide with the most trial data, shows how common these reactions are. In its 26-week trials, the tesamorelin label reports injection site reactions, including redness, itching, pain, irritation and bruising, in 17 percent of people on the drug compared with 6 percent on placebo. The label’s main advice is to rotate sites to reduce them.
Our answer on whether peptide injections hurt covers technique that keeps site reactions to a minimum.
What side effects come with growth hormone peptides?
Growth hormone peptides add effects that come from raising growth hormone itself. The tesamorelin label describes fluid retention linked to growth hormone release, showing up as swelling, joint aches and sometimes carpal tunnel symptoms such as numb or tingling fingers, which it says are either temporary or resolve when treatment stops.
| Effect in tesamorelin’s 26-week trials | Tesamorelin | Placebo |
|---|---|---|
| Injection site reactions (combined) | 17% | 6% |
| Joint pain (arthralgia) | 13% | 11% |
| Swelling in the legs or hands (peripheral edema) | 6% | 2% |
| Muscle pain (myalgia) | 6% | 2% |
| Pain in an arm or leg | 6% | 5% |
The somatropin (Genotropin) label describes the same pattern with growth hormone itself in adults: fluid retention, swelling and joint pain that are usually temporary and related to dose. Sermorelin works through the same pathway as tesamorelin and has far less published trial data, so the same effects are watched for.
Why does blood sugar need watching?
Because growth hormone works against insulin. The somatropin label warns that growth hormone may decrease insulin sensitivity, particularly at higher doses in susceptible people. For tesamorelin, the label asks for a glucose check before starting and periodic monitoring after, and its trials showed the shift: 5 percent of people on tesamorelin reached a diabetes-range A1C of 6.5 percent or higher by 26 weeks, against 1 percent on placebo.
That is why fasting glucose and A1C belong in your baseline and follow-up labs, and why men with prediabetes or diabetes need a careful conversation first. Our page on blood work before peptide therapy explains the baseline, and our answer on peptide therapy with diabetes covers the extra precautions.
What about BPC-157, TB-500 and GHK-Cu?
The honest answer is that their side effects in people are not well described. The FDA’s notes on these bulk substances flag a possible risk of immune reactions for injected forms, along with concerns about peptide-related impurities. For TB-500, the agency identified no human exposure data, and for injectable GHK-Cu it cited limited human data.
Their supply status is also unsettled in 2026. They left the FDA’s safety-concern list in April, and an advisory committee recommended BPC-157 and TB-500 for compounding in July, but no final rule exists. Questions about long-term risks, including cancer, are covered in our answer on whether peptides increase cancer risk.
Which reactions need urgent care?
Most side effects can wait for a call to your provider; a few cannot. The tesamorelin label reports hypersensitivity reactions in 4 percent of trial patients and says treatment should stop immediately if one occurs.
Call your provider the same day for:
- redness, warmth or swelling at a site that keeps spreading, or a fever;
- new swelling in your legs, hands or face;
- numbness or tingling in your fingers that does not settle;
- very high home blood sugar readings, or unusual thirst and urination.
If your face or throat swells, you struggle to breathe or you feel faint after a dose, call 911 right away.
How Ultimate Male monitors side effects
Every plan in our peptide therapy program starts with blood work, including IGF-1, metabolic and hormone markers, and a one-on-one consultation at San Gabriel or Downey. Your first injection is shown in clinic, and follow-up labs with a check-in at six to eight weeks let your provider compare IGF-1 and blood sugar against your baseline.
If side effects appear, your provider may recheck IGF-1, review your technique and storage, or adjust the dose, and stopping is on the table if they persist. For sermorelin and tesamorelin alike, your provider sets and changes the dose. The free 10-minute call is the place to ask about any side effect before you start.
